# Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

> **NCT01255358** · PHASE2 · COMPLETED · sponsor: **Quince Therapeutics S.p.A.** · enrollment: 22 (actual)

## Conditions studied

- Nervous System Disorder
- Genetic Syndrome

## Interventions

- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01255358
- **Lead sponsor:** Quince Therapeutics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-09
- **Final completion:** 2011-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01255358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01255358, "Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01255358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*